Central Trust Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Central Trust Company’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.69K	Hold	17	–	–	﹤0.01%	1388
2026 Q1	$2.17K	Buy	17 +1	+6%	+$125	﹤0.01%	1361
2025 Q4	$1.95K	Sell	16 -8	-33%	-$917	﹤0.01%	1330
2025 Q3	$2.4K	Hold	24	–	–	﹤0.01%	1276
2025 Q2	$1.99K	Buy	+24	New	+$1.92K	﹤0.01%	1322
2025 Q1	–	Sell	-176	Closed	-$15.9K	–	1495
2024 Q4	$15.9K	Hold	176	–	–	﹤0.01%	1007
2024 Q3	$17.4K	Sell	176 -150	-46%	-$14.7K	﹤0.01%	983
2024 Q2	$30.2K	Buy	326 +150	+85%	+$13.4K	﹤0.01%	871
2024 Q1	$16.7K	Hold	176	–	–	﹤0.01%	989
2023 Q4	$15.7K	Buy	+176	New	+$13.1K	﹤0.01%	991
2022 Q2	–	Sell	-350	Closed	-$31K	–	1470
2022 Q1	$31K	Hold	350	–	–	﹤0.01%	884
2021 Q4	$39K	Hold	350	–	–	﹤0.01%	835
2021 Q3	$44K	Hold	350	–	–	﹤0.01%	788
2021 Q2	$47K	Hold	350	–	–	﹤0.01%	746
2021 Q1	$47K	Hold	350	–	–	﹤0.01%	709
2020 Q4	$49K	Buy	+350	New	+$44.8K	﹤0.01%	690
2019 Q2	–	Sell	-100	Closed	-$9K	–	1186
2019 Q1	$9K	Sell	100 -35	-26%	-$2.98K	﹤0.01%	919
2018 Q4	$10K	Sell	135 -270	-67%	-$21.8K	﹤0.01%	902
2018 Q3	$39K	Sell	405 -15	-4%	-$1.45K	﹤0.01%	725
2018 Q2	$40K	Sell	420 -190	-31%	-$17.5K	﹤0.01%	708
2018 Q1	$54K	Sell	610 -105	-15%	-$9.59K	﹤0.01%	676
2017 Q4	$61K	Hold	715	–	–	﹤0.01%	669
2017 Q3	$62K	Buy	715 +10	+1%	+$802	﹤0.01%	646
2017 Q2	$54K	Buy	705 +570	+422%	+$40.4K	﹤0.01%	679
2017 Q1	$9K	Hold	135	–	–	﹤0.01%	984
2016 Q4	$8K	Hold	135	–	–	﹤0.01%	1032
2016 Q3	$9K	Buy	+135	New	+$8.35K	﹤0.01%	966

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Central Trust Company's XBI Position: Q2 2026 in Review

Central Trust Company held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 17 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Central Trust Company first reported a position in XBI in Q3 2016 and has held it in 27 quarters since. The position peaked at $62K in Q3 2017. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Central Trust Company held 17 shares of State Street SPDR S&P Biotech ETF worth $2.69K as of Q2 2026.
Central Trust Company left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1388 holding.
Central Trust Company first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and has held it in 27 quarters since.
Central Trust Company's State Street SPDR S&P Biotech ETF position peaked at $62K in Q3 2017.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.